Alvotech
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALVO research report →
About the company
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira.
- CEO
- Lisa Graver
- IPO
- 2022
- Employees
- 1,012
- HQ
- Luxembourg, IS
Price Chart
- Market Cap
- $1.22B
- P/E
- -14.77
- P/S
- 2.18
- P/B
- -4.22
- EV/EBITDA
- 50.44
- Div Yield
- 0.00%
- Gross Margin
- 61.35%
- Op Margin
- 13.80%
- Net Margin
- -14.43%
- ROE
- 35.22%
- ROIC
- -11.66%
- Revenue
- $586.32M · 19.74%
- Net Income
- $27.92M · 112.04%
- EPS
- $0.10 · 111.49%
- Op Income
- $78.21M
- FCF YoY
- 60.98%
- 52W High
- $9.94
- 52W Low
- $2.94
- 50D MA
- $3.57
- 200D MA
- $4.96
- Beta
- 0.21
- Avg Volume
- 682.21K
Get TickerSpark's AI analysis on ALVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALVO coverage
Recent articles, reports, and earnings notes.
No research on ALVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALVO report →Similar companies
Peers in the same neighborhood.